Bio-Techne Corp.
(NASDAQ : TECH)

( )
TECH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.00%283.741.5%$847.25m
GILDGilead Sciences, Inc. 0.00%86.261.0%$795.01m
MRNAModerna, Inc. -0.52%175.490.0%$765.23m
VRTXVertex Pharmaceuticals, Inc. -0.11%312.631.9%$481.47m
REGNRegeneron Pharmaceuticals, Inc. -0.50%732.552.6%$470.92m
BIIBBiogen, Inc. -3.37%294.881.8%$343.12m
ILMNIllumina, Inc. -0.70%217.463.2%$268.84m
SNSSSunesis Pharmaceuticals, Inc. 0.00%2.780.7%$194.33m
BMRNBioMarin Pharmaceutical, Inc. 0.00%96.924.2%$161.47m
BNTXBioNTech SE -0.19%154.550.0%$151.82m
MRTXMirati Therapeutics, Inc. 0.00%98.621.6%$132.21m
TECHBio-Techne Corp. 0.00%338.974.5%$123.89m
AXSMAxsome Therapeutics, Inc. 0.00%56.821.6%$80.71m
NVAXNovavax, Inc. 0.00%16.5475.3%$70.44m
HALOHalozyme Therapeutics, Inc. 0.00%54.6718.4%$64.50m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.